Angiotech at neutral by Merrill

Angiotech Pharmaceuticals Inc. was rated by Merrill Lynch analyst Hari Sambasivam at neutral after data released at the Transcatheter Cardiovascular Therapeutics meeting showed that Abbott's ZoMaxx drug-eluting stent failed to show non-inferiority in a head-to-head study with Taxus. According to the analyst, the Taxus stent showed statistically superior data for in-segment late loss and restenosis compared to ZoMaxx, with no statistical difference in safety as measured by the rate of major adverse coronary events. The ZoMaxx stent is a zotarolimus-eluting stainless steel stent with a phosphorylcholine coating that Abbott had said it was discontinuing development of in favor of the Xience V stent. Share of the Vancouver, B.C.-based medical technology company were down 13 cents, or 1.37%, at $9.35. (Nasdaq: ANPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.